24 October 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
Placing to Raise A$200,000
Argent BioPharma, an innovative multidisciplinary drug development company within the biopharmaceutical sector, announces that it has received firm commitments from a professional and sophisticated investor to raise A$200,000 (Placement) through the issue of 666,667 fully paid ordinary shares at A$0.30 per share (Placement Shares).
Proceeds from the Placement will support the continuation of the Company's drug development pipeline, including CannEpil® and CimetrA® in the US and EU markets and general working capital purposes.
The Placement Shares are to be issued under the Company's existing placement capacity in accordance with ASX listing Rule 7.1.
-Ends-
Authorised for release by the board of directors, for further information please contact:
| Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 | Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950
|
About Argent BioPharma
Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system ("CNS") and Immunology treatments.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
Total voting rights
On issue of the Fundraising Shares, the Company will have 54,272,269 Ordinary Shares in issue, each with one voting right. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 54,272,269 and this figure may be used by shareholders from issue of the Placing Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
